Whether youre already taking a GLP1 medication or thinking about starting one, staying active plays a powerful role in your success
The abdomen, thigh, and upper arm are all acceptable sites for both CagriSema and tirzepatide
GLP-1 receptor agonists e.g., semaglutide, liraglutide commonly cause gastrointestinal adverse effects such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort, especially during dose escalation, less common risks include pancreatitis, gallbladder disease, and hypoglycemia mainly with insulin sulfonylureas
It passes through your system without feeding beneficial bacteria
Furthermore, GLP-1 has been shown to downregulate inflammatory and oxidative stress pathways that are linked to atherosclerosis development [9,10,11]